{
    "eid": "2-s2.0-85169509907",
    "title": "First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection",
    "cover-date": "2023-01-01",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Hepatology",
            "@code": "2721",
            "@abbrev": "MEDI"
        }
    ],
    "keywords": [
        "Gene expression",
        "Hepatitis B virus",
        "Immune clearance",
        "Pharmacology",
        "Therapeutic use"
    ],
    "authors": [
        "Edward J. Gane",
        "Won Kim",
        "Tien Huey Lim",
        "Pisit Tangkijvanich",
        "Jung Hwan Yoon",
        "William Sievert",
        "Wattana Sukeepaisarnjaroen",
        "Alexander J. Thompson",
        "Vedran Pavlovic",
        "Bernadette Surujbally",
        "Cynthia Wat",
        "Bob D. Brown",
        "Hardean E. Achneck",
        "Man Fung Yuen"
    ],
    "citedby-count": 0,
    "ref-count": 37,
    "ref-list": [
        "Global hepatitis report",
        "Hepatitis B",
        "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study",
        "Rebound of HBV DNA after cessation of nucleos/tide analogues in chronic hepatitis B patients with undetectable covalently closed",
        "Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients",
        "Chronic hepatitis B: new potential therapeutic drugs target",
        "Covalently closed circular DNA: the ultimate therapeutic target for curing HBV infections",
        "Circulating serum HBsAg level is a biomarker for HBV-specific T and B cell responses in chronic hepatitis B patients",
        "Clinical study of single-stranded oligonucleotide RO7062931 in healthy volunteers and patients with chronic hepatitis B",
        "Association between seroclearance of hepatitis B surface antigen and long-term clinical outcomes of patients with chronic hepatitis B virus infection: systematic review and meta-analysis",
        "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection",
        "Guidance document. Chronic hepatitis B virus infection: developing drugs for treatment",
        "Defective T-cell immunity in hepatitis B virus infection: why therapeutic vaccination needs a helping hand",
        "Guidance for design and endpoints of clinical trials in chronic hepatitis B - Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference(double dagger)",
        "GalNAc-siRNA conjugates: prospective tools on the frontier of anti-viral therapeutics",
        "Dicerna 2020 virtual R&D update: nedosiran, RG6346 and going beyond GalXC\u2122",
        "Insights into hepatitis B virus DNA integration-55 years after virus discovery",
        "GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics",
        "Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug",
        "Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates",
        "Natural history of chronic hepatitis B REVEALed",
        "High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load",
        "Quantitative levels of hepatitis B virus DNA and surface antigen and the risk of hepatocellular carcinoma in patients with hepatitis B receiving long-term nucleos(t)ide analogue therapy",
        "HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability",
        "HBsAg quantification: useful for monitoring natural history and treatment outcome",
        "Hepatitis B cure: from discovery to regulatory approval",
        "Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: a meta-analysis",
        "Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study",
        "The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment",
        "Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study)",
        "RNA interference therapy for chronic hepatitis B predicts the importance of addressing viral integration when developing novel cure strategies",
        "Immune response in hepatitis B virus infection",
        "HBeAg-negative/Anti-HBe-positive chronic hepatitis B: a 40-year-old history",
        "The functions of hepatitis B virus encoding proteins: viral persistence and liver pathogenesis",
        "Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance",
        "Liver safety assessment in clinical trials of new agents for chronic hepatitis B",
        "Is alanine aminotransferase flare-up in nucleos(t)ide analogue treatment of chronic hepatitis B a promising, rather than a devastating, sign?"
    ],
    "affiliation": [
        {
            "affiliation-city": "Hong Kong",
            "@id": "60114498",
            "affilname": "The University of Hong Kong, State Key Laboratory of Liver Research",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60114498",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60026553",
            "affilname": "University of Melbourne",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60026553",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60021119",
            "affilname": "Seoul National University Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60021119",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Melbourne",
            "@id": "60019578",
            "affilname": "Monash University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60019578",
            "affiliation-country": "Australia"
        },
        {
            "affiliation-city": "Khon Kaen",
            "@id": "60017165",
            "affilname": "Khon Kaen University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60017165",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Auckland",
            "@id": "60011750",
            "affilname": "Auckland City Hospital",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60011750",
            "affiliation-country": "New Zealand"
        },
        {
            "affiliation-city": "Hong Kong",
            "@id": "60006541",
            "affilname": "The University of Hong Kong",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60006541",
            "affiliation-country": "Hong Kong"
        },
        {
            "affiliation-city": "Auckland",
            "@id": "60004203",
            "affilname": "Middlemore Hospital, Auckland",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60004203",
            "affiliation-country": "New Zealand"
        },
        {
            "affiliation-city": "Welwyn Garden City",
            "@id": "60001946",
            "affilname": "Roche Products Limited UK",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60001946",
            "affiliation-country": "United Kingdom"
        },
        {
            "affiliation-city": "Seoul",
            "@id": "60000656",
            "affilname": "Seoul National University College of Medicine",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60000656",
            "affiliation-country": "South Korea"
        },
        {
            "affiliation-city": "Lexington",
            "@id": "129484383",
            "affilname": "a Novo Nordisk Company",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/129484383",
            "affiliation-country": "United States"
        }
    ],
    "funding": [
        "Dicerna Pharmaceuticals, Inc.",
        "Dicerna Pharmaceuticals, Inc. a Novo Nordisk",
        "Dicerna Pharmaceuticals, Inc. a Novo Nordisk Company",
        "Novo Nordisk Company",
        "Novo Nordisk"
    ]
}